Health
Novo Nordisk launches first and only multi-month subscription program for FDA-approved Wegovy®, offering savings of up to $1,200/year
Novo Nordisk today announced a new multi-month subscription program for Wegovy® (semaglutide) that provides eligible self-pay patients who enroll in the program through select telehealth providers a lower, predictable monthly price. The program is designed to reduce cost uncertainty and help people start and stay on FDA-approved obesity treatment.
About this update from Novo Nordisk A/s Class B
[{"type":"list","items":[{"val":[{"type":"text","content":"New subscription-based option helps eligible self-pay patients start and stay on Wegovy® with predictable pricing","length":113,"tagName":"p"}]},{"val":[{"type":"text","content":"Available March 31, 2026, through Ro, WeightWatchers, LifeMD, with Hims & Hers, Sesame, and other telehealth providers coming online soon","length":146,"tagName":"p"}]},{"val":[{"type":"text","content":"Program builds on Novo Nordisk's efforts to meet patients where they seek care and expand affordable options to access authentic, FDA-approved Wegovy®","length":154,"tagName":"p"}]},{"val":[{"type":"text","content":"Wegovy® offers adults with obesity significant weight loss, along with diet and exercise, and is FDA-approved to lower the risk of major CV events such as death, heart attack, or stroke in adults with obesity with known heart disease — a claim only Wegovy® can make","length":265,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":678,"olType":false},{"type":"text","content":"PLAINSBORO, N.J., March 31, 2026 /PRNewswire/ -- Novo Nordisk today announced a new multi-month subscription program for Wegovy® (semaglutide) that provides eligible self-pay patients who enroll in the program through select telehealth providers a lower, predictable monthly price. The program is designed to reduce cost uncertainty and help people start and stay on FDA-approved obesity treatment.","length":398,"tagName":"p"},{"type":"image","alt":"Novo Logo (PRNewsfoto/Novo Nordisk)","displaySize":"","headline":null,"caption":"Novo Logo (PRNewsfoto/Novo Nordisk)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":284,"url":"https://media.zenfs.com/en/prnewswire.com/4b2f344794d2390acbb0680ef27be374"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/fGU.RQUd08mIdJRTww3UZw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTUwMQ--/https://media.zenfs.com/en/prnewswire.com/4b2f344794d2390acbb0680ef27be374","width":400,"height":284}},"href":"https://mma.prnewswire.com/media/2751477/novo_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":""The new Wegovy® subscription program removes barriers, providing people who enroll a simple, affordable, and consistent way to start and stay on genuine, FDA-approved treatment," said Ed Cinca, senior vice president, Marketing & Pati...